Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells

24 Aug 2021

Abstract excerpt

BACKGROUND: Taking advantage of nanobodies (Nbs) in immunotherapy, we investigated the cytotoxicity of Nb-based chimeric antigen receptor T cells (Nb CAR-T) against lymphoma cells. METHODS: CD19 Nb CAR-T, CD20 Nb CAR-T, and Bispecific Nb CAR-T cells were generated by panning anti-human CD19- and CD20-specific nanobody sequences from a natural Nb-expressing phage display library, integrating Nb genes with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34429118
DOI: 10.1186/s12935-021-02151-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cellsPMID 34429118Read ↗

Nanobody Armed T Cells Endow CAR-T Cells the Ability to Against Lymphoma CellsSemantic proximity Read ↗

The Application of Nanobody in CAR-T TherapySemantic proximity Read ↗

Phage Display-Based Nanotechnology Applications in Cancer ImmunotherapySemantic proximity Read ↗

Nanobody-based CAR-T cells for cancer immunotherapySemantic proximity Read ↗

CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B CellsSemantic proximity Read ↗

The arming of NK cells with Fc-engineered rituximab confers them specificity against CD20-expressing cellsSemantic proximity Read ↗

Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphomaSemantic proximity Read ↗

Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphomaSemantic proximity Read ↗

CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphomaSemantic proximity Read ↗

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read ↗

Progress on Phage Display Technology: Tailoring Antibodies for Cancer ImmunotherapySemantic proximity Read ↗

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.